Is Minimal Residual Disease Monitoring Clinically Relevant in Adults with Acute Myelogenous Leukemia?
Is Minimal Residual Disease Monitoring Clinically Relevant in Adults with Acute Myelogenous Leukemia?
复制标题
DOI：
10.1007/s11899-013-0157-2
复制
发表时间：
2013-06-01
影响因子：
2.9
通讯作者：
Guzman, Monica L.
中科院分区：
文献类型：
--
作者：
Carlson, Karen-Sue B.;Guzman, Monica L.
在过去的一年里，人们越来越重视了解微小残留病(MRD)评估的临床相关性。在治疗的不同阶段监测MRD水平具有相当大的潜力，可以影响AML患者的治疗指导并改善结果。因此，已加紧努力解决有关MRD测量的重要关切。这些问题包括：(1)应该监测什么；(2)应该使用什么方法；(3)这种方法是否在实验室之间标准化；(4)如何定义预后水平；(5)何时应该监测MRD；以及(6)对MRD阳性患者有什么治疗选择。在这篇综述中，我们将讨论可用于MRD的方法，以及迄今旨在解决围绕AML患者使用MRD测量的担忧的研究。
In the past year, there has been increasing attention towards understanding the clinical relevance of minimal residual disease (MRD) assessment. The monitoring of MRD levels at various stages of therapy has considerable potential to impact the guidance of treatment for AML patients and improve outcomes. Thus, efforts have increased to address important concerns regarding MRD measurements. These concerns include: (1) what should be monitored; (2) what methodologies should be used; (3) whether such methodologies are standardized across laboratories; (4) how prognostic levels are defined; (5) when MRD should be monitored; and (6) what treatment options are available for MRD positive patients. In this review, we will discuss the methodologies available for MRD and the studies available to date aiming to address the concerns around the use of MRD measurements for AML patients.